Institution Logo

Sidney Kimmel Comprehensive Cancer Center at Jefferson Health

Kidney Cancer Program

Address

1025 Walnut Street
Philadelphia, PA, 19107
(800) 533-3669
Appointments: (215) 955-1000
Program Website

Key Contacts

Medical Oncology Lead:
Dr. Kevin Zarrabi – Assistant Professor
Urologic Surgery Lead:
Dr. Adam Metwalli – Professor
Patient Navigator & Appointments:
Call (215) 955-1000
Clinical Trials Contact:
[email protected]
(215) 600-9151

Volume

Metrics reflect this center’s demonstrated experience across key areas of kidney cancer care.

Kidney Cancer Surgery Volume

Very High

Clear Cell Kidney Cancer Diagnosis Volume

High

Non–Clear Cell Kidney Cancer Diagnosis Volume

Very High

Clinical Trial Participation Volume

Very High

Radiation & Ablation Procedure Volume

Medium

About these ratings

Volume and expertise levels are determined using standardized thresholds established by the Kidney Cancer Association and updated annually. Metrics are based on available data and may not reflect the full scope of a center’s capabilities or activity. These metrics are intended to help patients identify centers with demonstrated experience in kidney cancer care.

Types of Services Offered

Clinical Trials End of Life Services Genetic Counseling Infusion Center Integrated Multidisciplinary Clinic Integrative Oncology Molecular Testing Oncology Urgent Care Clinic Patient Case Discussions / Tumor Boards Precision Medicine Supportive Care / Pain Clinics Survivorship Clinics Interventional Radiology Medical Oncology Pain Management Palliative Care Pathology Radiation Oncology Radiology Urologic Surgery

Kidney Cancer Types & Expertise

Chromophobe RCC Clear Cell RCC Collecting Duct RCC FH-deficient RCC Papillary RCC Renal Medullary Carcinoma Sarcomatoid Translocation RCC Tuberous Sclerosis–associated RCC Unclassified RCC VHL-associated RCC Bilateral Kidney Tumors Complex Recurrent Cases Cystic Renal Tumors Hereditary Syndromes Kidney Transplant Recipients Pregnancy Solitary Kidney Young Adult (age 18-50)

Special Programs, Recognitions & Outcomes

American College of Surgeons Accredited Cancer Program Government-Funded Research NCI Designated Cancer Center

Research Programs

Clinical Multi-Institutional Collaboration Population-Based Research Lab Translational

Multi-Institutional Collaborations

Society of Urologic Oncology- Clinical Trials Consortium (SUO-CTC)
NCI-Sponsored Networks & Trials
Multi-Institutional Clinical Trial Collaboration Published Internationally
Cross-Disciplinary Collaborations within SKCCC & Beyond

Patient Resources & Support Services

Art Therapy Fertility Preservation Counseling Financial Navigators Interpreter Services Lodging / Long-Term Housing Lymphedema Therapy Music Therapy Nurse Navigators Nutrition Services / Dietician Occupational Therapy On-site Dispensing / Pharmacy Parking Assistance (valet or concierge) Pastoral / Spiritual Care Patient Navigators Peer Support Options Physical Therapy Psychiatrists / Psychologists Social Workers / Counselors Transportation Service Wellness Center

Insurance Carriers

Accepted

  • Aetna
  • AmeriHealth regional plans
  • Cigna
  • Horizon Blue Cross Blue Shield of NJ
  • Independence Blue Cross
  • Humana
  • UnitedHealthcare
  • Medicare
  • Medicaid
  • Children's Health Insurance Program
  • Jefferson Health Plans Medicare Advantage
  • Jefferson Health Plans Medicaid & CHIP

Open Clinical Trials

A phase 1/1b first-in-human (FIH) study of JZP898 as monotherapy and in combination with pembrolizumab in adult patients with advanced or metastatic solid tumors

JZP898 is a conditionally activated prodrug of interferon alpha (IFNα) that can preferentially deliver IFNα to the tumor microenvironment while potentially minimizing systemic IFNα therapy-associated toxicity

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

This is a multi-site, three-cohort phase II trial of cabozantinib for IMDC all-risk frontline metastatic renal cell carcinoma (mRCC) patients OR any line mRCC patients who have not previously been treated with cabozantinib, and patients with pancreatic or extra-pancreatic neuroendocrine tumors.

Request an Appointment